Advances in the management of low- to intermediate-risk myelodysplastic syndrome: Integrating the National Comprehensive Cancer Network guidelines.
Myelodysplastic syndromes (MDSs) are a group of hematologic diseases that present unique challenges for oncology nurses, especially because patients with the disorders are being seen more often in oncology practices. An increasing array of therapeutic options are available, and the National Comprehensive Cancer Network published its first clinical practice guidelines for MDSs in 2004. This article provides oncology nurses with the most recent data on supportive care as well as emerging therapies for patients with low- to intermediate-risk MDS.
Kurtin
Sandra E
SE
Arizona Cancer Center, Tucson, USA. skurtin@umcaz.edu
D000368:Aged; D000465:Algorithms; D000753:Anemia, Refractory / Q000188:drug therapy / Q000628:therapy; D015507:Drugs, Investigational; D005260:Female; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000451:nursing / Q000628:therapy; D017410:Practice Guidelines as Topic; D018570:Risk Assessment
D015507:Drugs, Investigational